BE1022792B1 - Molecule support - Google Patents

Molecule support Download PDF

Info

Publication number
BE1022792B1
BE1022792B1 BE2015/5496A BE201505496A BE1022792B1 BE 1022792 B1 BE1022792 B1 BE 1022792B1 BE 2015/5496 A BE2015/5496 A BE 2015/5496A BE 201505496 A BE201505496 A BE 201505496A BE 1022792 B1 BE1022792 B1 BE 1022792B1
Authority
BE
Belgium
Prior art keywords
seq
polypeptide
amino acid
acid sequence
saccharide
Prior art date
Application number
BE2015/5496A
Other languages
English (en)
French (fr)
Other versions
BE1022792A1 (fr
Inventor
Francesco Berti
Roberta Cozzi
Guido Grandi
Domenico Maione
Y Ros Immaculada Margarit
Daniela Cira Rinaudo
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Application granted granted Critical
Publication of BE1022792B1 publication Critical patent/BE1022792B1/fr
Publication of BE1022792A1 publication Critical patent/BE1022792A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BE2015/5496A 2014-08-05 2015-08-05 Molecule support BE1022792B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14179945 2014-08-05
EP14179945.2 2014-08-05

Publications (2)

Publication Number Publication Date
BE1022792B1 true BE1022792B1 (fr) 2016-09-06
BE1022792A1 BE1022792A1 (fr) 2016-09-06

Family

ID=51298571

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2015/5496A BE1022792B1 (fr) 2014-08-05 2015-08-05 Molecule support

Country Status (16)

Country Link
US (1) US10245310B2 (enExample)
EP (1) EP3177324A1 (enExample)
JP (1) JP2017523985A (enExample)
KR (1) KR20170039709A (enExample)
CN (1) CN108064174A (enExample)
AR (1) AR101455A1 (enExample)
AU (1) AU2015299008B2 (enExample)
BE (1) BE1022792B1 (enExample)
BR (1) BR112017002183A2 (enExample)
CA (1) CA2957118A1 (enExample)
EA (1) EA201790239A1 (enExample)
IL (1) IL250238A0 (enExample)
MX (1) MX2017001638A (enExample)
SG (1) SG11201700673RA (enExample)
WO (1) WO2016020413A1 (enExample)
ZA (1) ZA201700824B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007000341A2 (en) * 2005-06-27 2007-01-04 Glaxosmithkline Biologicals S.A. Immunogenic composition
US20210108002A1 (en) 2016-12-06 2021-04-15 Glaxosmithkline Biologicals Sa Purification Process For Capsular Polysaccharide
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
WO2018126229A2 (en) 2016-12-30 2018-07-05 Sutrovax, Inc. Polypeptide-antigen conjugates with non-natural amino acids
JP2020515629A (ja) * 2017-04-04 2020-05-28 アヴィディア テクノロジーズ， インコーポレイテッド 免疫応答を誘導するためのペプチドベースのワクチン、それらの製造方法および使用
EP3638301A1 (en) 2017-06-16 2020-04-22 GlaxoSmithKline Biologicals S.A. Method of treatment
WO2019217665A1 (en) * 2018-05-09 2019-11-14 West Virginia University Iron-acquisition receptor peptide administration for vaccination against pseudomonas aeruginosa
EP3574915A1 (en) * 2018-05-29 2019-12-04 Neovacs Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
JP7399934B2 (ja) * 2018-07-04 2023-12-18 バックスサイト・インコーポレイテッド 免疫原性複合体の改良
WO2020010000A1 (en) * 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
CN108840914B (zh) * 2018-08-13 2022-07-01 内蒙古民族大学 一种具有免疫原性的多肽、其抗体的制备方法以及用途
BR112021019826A2 (pt) * 2019-04-02 2021-12-07 Vaxcyte Inc Síntese otimizada de antígeno de plasmídeo de invasão b livre de célula e composições e métodos de uso relacionados
CA3161857A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
US20230250142A1 (en) * 2020-06-12 2023-08-10 Glaxosmithkline Biologicals Sa Dock tag system
EP4165065A2 (en) 2020-06-12 2023-04-19 GlaxoSmithKline Biologicals S.A. Gbs ferritin nanoparticles
CN112979797B (zh) * 2021-04-28 2022-04-01 中国检验检疫科学研究院 一种抗赤羽病病毒单克隆抗体及其制备方法与应用
GB202215634D0 (en) * 2022-10-21 2022-12-07 Glaxosmithkline Biologicals Sa Polypeptide scaffold

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069200A2 (en) * 2004-12-22 2006-06-29 Novartis Vaccines And Diagnostics Inc. Group b streptococcus
WO2006078318A2 (en) * 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
WO2009027768A2 (en) * 2006-07-26 2009-03-05 Novartis Ag Immunogenic compositions for gram positive bacteria
WO2009101403A1 (en) * 2008-02-11 2009-08-20 Novartis Ag Hybrid polypeptides comprising gbs-80 and spb1 proteins of streptococcus
WO2010079464A1 (en) * 2009-01-12 2010-07-15 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
GB2478203A (en) * 2010-02-26 2011-08-31 Novartis Ag Polypeptides and compositions for the treatment of Streptococcus agalactiae infection
WO2011121576A2 (en) * 2010-04-01 2011-10-06 Novartis Ag Immunogenic proteins and compositions
WO2013030783A1 (en) * 2011-08-30 2013-03-07 Novartis Ag Immunogenic proteins and compositions
WO2013124473A1 (en) * 2012-02-24 2013-08-29 Novartis Ag Pilus proteins and compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0502095D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0605757D0 (en) * 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006078318A2 (en) * 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
WO2006069200A2 (en) * 2004-12-22 2006-06-29 Novartis Vaccines And Diagnostics Inc. Group b streptococcus
WO2009027768A2 (en) * 2006-07-26 2009-03-05 Novartis Ag Immunogenic compositions for gram positive bacteria
WO2009101403A1 (en) * 2008-02-11 2009-08-20 Novartis Ag Hybrid polypeptides comprising gbs-80 and spb1 proteins of streptococcus
WO2010079464A1 (en) * 2009-01-12 2010-07-15 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
GB2478203A (en) * 2010-02-26 2011-08-31 Novartis Ag Polypeptides and compositions for the treatment of Streptococcus agalactiae infection
WO2011121576A2 (en) * 2010-04-01 2011-10-06 Novartis Ag Immunogenic proteins and compositions
WO2013030783A1 (en) * 2011-08-30 2013-03-07 Novartis Ag Immunogenic proteins and compositions
WO2013124473A1 (en) * 2012-02-24 2013-08-29 Novartis Ag Pilus proteins and compositions

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHENG QI ET AL: "Antibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B streptococci", INFECTION AND IMMUNITY, vol. 69, no. 4, April 2001 (2001-04-01), pages 2302 - 2308, XP002336337, ISSN: 0019-9567, DOI: 10.1128/IAI.69.4.2302-2308.2001 *
G. LINDAHL ET AL: "Surface Proteins of Streptococcus agalactiae and Related Proteins in Other Bacterial Pathogens", CLINICAL MICROBIOLOGY REVIEWS, vol. 18, no. 1, 2005, pages 102 - 127, XP055166916, ISSN: 0893-8512, DOI: 10.1128/CMR.18.1.102-127.2005 *
K. FLUEGGE ET AL: "Identification and immunoreactivity of proteins released from Streptococcus agalactiae", EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, vol. 23, no. 11, November 2004 (2004-11-01), pages 818 - 824, XP055129256, ISSN: 0934-9723, DOI: 10.1007/s10096-004-1229-y *
LAWRENCE C. PAOLETTI ET AL: "Vaccines to prevent neonatal GBS infection", SEMINARS IN NEONATOLOGY, vol. 7, no. 4, August 2002 (2002-08-01), pages 315 - 323, XP055166924, ISSN: 1084-2756, DOI: 10.1053/siny.2002.0114 *
MADOFF L C ET AL: "MATERNAL IMMUNIZATION OF MICE WITH GROUP B STREPTOCOCCAL TYPE III POLYSACCHARIDE-BETA C PROTEIN CONJUGATE ELICITS PROTECTIVE ANTIBODY TO MULTIPLE SEROTYPES", JOURNAL OF CLINICAL INVESTIGATION, vol. 94, July 1994 (1994-07-01), pages 286 - 292, XP002923461, ISSN: 0021-9738, DOI: 10.1172/JCI117319 *
MONIKA BRZYCHCZY-WLOCH ET AL: "Identification of high immunoreactive proteins from Streptococcus agalactiae isolates recognized by human serum antibodies", FEMS MICROBIOLOGY LETTERS, vol. 349, 24 October 2013 (2013-10-24), pages 61 - 70, XP055129245, ISSN: 0378-1097, DOI: 10.1111/1574-6968.12292 *

Also Published As

Publication number Publication date
EP3177324A1 (en) 2017-06-14
SG11201700673RA (en) 2017-02-27
AU2015299008A1 (en) 2017-02-23
CA2957118A1 (en) 2016-02-11
MX2017001638A (es) 2017-04-27
US10245310B2 (en) 2019-04-02
BE1022792A1 (fr) 2016-09-06
WO2016020413A1 (en) 2016-02-11
IL250238A0 (en) 2017-03-30
AR101455A1 (es) 2016-12-21
EA201790239A1 (ru) 2017-07-31
ZA201700824B (en) 2019-07-31
CN108064174A (zh) 2018-05-22
AU2015299008B2 (en) 2018-08-02
KR20170039709A (ko) 2017-04-11
BR112017002183A2 (pt) 2018-01-16
US20170224803A1 (en) 2017-08-10
JP2017523985A (ja) 2017-08-24

Similar Documents

Publication Publication Date Title
BE1022792B1 (fr) Molecule support
CN104080479B (zh) 包括spr0096和spr2021抗原的运载体分子
CN103209708B (zh) 免疫原性组合物
US9040055B2 (en) Conjugation of streptococcal capsular saccharides
US10736959B2 (en) Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
US20130315960A1 (en) Conjugated beta-1,3-linked glucans
BE1024282B1 (fr) Compositions immunogènes

Legal Events

Date Code Title Description
MM Lapsed because of non-payment of the annual fee

Effective date: 20240831